Alternative approaches to IP regulation
DavidLegge (Talk | contribs) |
|||
| (2 intermediate revisions by one user not shown) | |||
| Line 1: | Line 1: | ||
| − | + | Official Australian policy (produced by the ARC, AVCC, NHMRC, DETYA, etc etc in 2001; [http://www.nhmrc.gov.au/funding/policy/_files/ipman.pdf National Principles of Intellectual Property Management of Publicly Funded Research]) says very little about the implications of Australian patenting and licensing policies for promoting access to essential medicines in developing countries.</br> | |
| − | + | In fact there is a wide range of alternatives to the exclusive patent model, many of which could contribute to to promoting wider access. These include: non-exclusive patenting; open source licensing conditions; patent pools; and the medical prize proposal. | |
| − | + | Open source licensing is of particular relevance to publicly funded research institutions who undertake much of the cost of developing new pharmaceuticals. | |
| − | + | Chaifetz, S., et al., Closing the access gap for health innovations: an open licensing proposal for universities. 2007. Globalisation and Health 3:1, p. 1. [[http://www.globalizationandhealth.com/content/3/1/1 web link]]</br> | |
| − | + | Universities Allied for Essential Medicines [[http://www.essentialmedicine.org/ web link]]. Statement of Principles [[http://www.petitiononline.com/uaemuw/petition.html Principles]]</br> | |
| − | + | Report of WHO Commission on Intellectual Property Rights, Innovation and Public Health [[http://www.who.int/intellectualproperty/en/ Web link]]</br> | |
| − | + | Brewster et al (2005) [[http://www.biodevelopments.org/innovation/ist3.pdf Innovation Strategy Today]]</br> | |
| − | + | ICRISAT Policy on IPRs [[http://www.icrisat.org/ip_management/policy.htm IP management]]</br> | |
| − | + | Possible role for patent pooling in managing SARS [[http://www.who.int/bulletin/volumes/83/9/707.pdf Patent Pooling]]</br> | |
| − | + | Patent pools [[http://www.uspto.gov/web/offices/pac/dapp/opla/patentpool.pdf Patent Pools]]</br> | |
| − | Stiglitz on the Medical Prize Fund [[http://www.bmj.com/cgi/content/full/333/7582/1279 BMJ]] | + | Anti-commons in biomedical research [[http://0-find.galegroup.com.alpha2.latrobe.edu.au/itx/infomark.do?&contentSet=IAC-Documents&type=retrieve&tabID=T002&prodId=EAIM&docId=A20606179&source=gale&srcprod=EAIM&userGroupName=latrobe&version=1.0 Anticommons]]</br> |
| + | |||
| + | Stiglitz on the Medical Prize Fund [[http://www.bmj.com/cgi/content/full/333/7582/1279 BMJ]]</br> | ||
| + | |||
| + | [[Intellectual Property and Pharmaceuticals|Back to IP home]]</br> | ||
| + | [[PHM_Oz_IP_Project|IP Project Page]] | ||
Latest revision as of 04:48, 12 July 2007
Official Australian policy (produced by the ARC, AVCC, NHMRC, DETYA, etc etc in 2001; National Principles of Intellectual Property Management of Publicly Funded Research) says very little about the implications of Australian patenting and licensing policies for promoting access to essential medicines in developing countries.</br>
In fact there is a wide range of alternatives to the exclusive patent model, many of which could contribute to to promoting wider access. These include: non-exclusive patenting; open source licensing conditions; patent pools; and the medical prize proposal.
Open source licensing is of particular relevance to publicly funded research institutions who undertake much of the cost of developing new pharmaceuticals.
Chaifetz, S., et al., Closing the access gap for health innovations: an open licensing proposal for universities. 2007. Globalisation and Health 3:1, p. 1. [web link]</br>
Universities Allied for Essential Medicines [web link]. Statement of Principles [Principles]</br>
Report of WHO Commission on Intellectual Property Rights, Innovation and Public Health [Web link]</br>
Brewster et al (2005) [Innovation Strategy Today]</br>
ICRISAT Policy on IPRs [IP management]</br>
Possible role for patent pooling in managing SARS [Patent Pooling]</br>
Patent pools [Patent Pools]</br>
Anti-commons in biomedical research [Anticommons]</br>
Stiglitz on the Medical Prize Fund [BMJ]</br>
